These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24833894)

  • 1. Efficacy and tolerability of agomelatine in the treatment of depression.
    Plesničar BK
    Patient Prefer Adherence; 2014; 8():603-12. PubMed ID: 24833894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine as monotherapy for major depression: an outpatient, open-label study.
    Pecenak J; Novotny V
    Neuropsychiatr Dis Treat; 2013; 9():1595-604. PubMed ID: 24174876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder.
    Levitan MN; Papelbaum M; Nardi AE
    Neuropsychiatr Dis Treat; 2015; 11():1149-55. PubMed ID: 25999720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults.
    Howland RH
    Neuropsychiatr Dis Treat; 2009; 5():563-76. PubMed ID: 19966905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of melatonin agonists.
    Cardinali DP; Pandi-Perumal SR; Srinivasan V; Spence DW; Trakht I
    Expert Rev Endocrinol Metab; 2008 Mar; 3(2):269-279. PubMed ID: 30764095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of Antidepressant Effects of Agomelatine and Bupropion by Hesperidin in Mice.
    Nadar JS; Kale PP; Kadu PK; Prabhavalkar K; Dhangar R
    Neurol Res Int; 2018; 2018():9828639. PubMed ID: 30510800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine for Depression in Schizophrenia: A Case-Series.
    Mutschler J; Rüsch N; Schönfelder H; Herwig U; Brühl AB; Grosshans M; Rössler W; Russmann H
    Psychopharmacol Bull; 2012 Feb; 45(1):35-43. PubMed ID: 27738367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine in unipolar depression in clinical practice: a retrospective chart review.
    Langan J; Shajahan P; Martin D; Carleton R
    Ther Adv Psychopharmacol; 2011 Dec; 1(6):175-80. PubMed ID: 23983944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine and its therapeutic potential in the depressed patient.
    Kennedy SH; Eisfeld BS
    Neuropsychiatr Dis Treat; 2007 Aug; 3(4):423-8. PubMed ID: 19300571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.
    Savino R; Polito AN; Marsala G; Ventriglio A; Di Salvatore M; De Stefano MI; Valenzano A; Marinaccio L; Bellomo A; Cibelli G; Monda M; Monda V; Messina A; Polito R; Carotenuto M; Messina G
    Brain Sci; 2023 Apr; 13(5):. PubMed ID: 37239206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.
    Fornaro M; Prestia D; Colicchio S; Perugi G
    Curr Neuropharmacol; 2010 Sep; 8(3):287-304. PubMed ID: 21358978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antidepressant Agomelatine Improves Memory Deterioration and Upregulates CREB and BDNF Gene Expression Levels in Unpredictable Chronic Mild Stress (UCMS)-Exposed Mice.
    Gumuslu E; Mutlu O; Sunnetci D; Ulak G; Celikyurt IK; Cine N; Akar F; Savlı H; Erden F
    Drug Target Insights; 2014; 8():11-21. PubMed ID: 24634580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mood disorders, circadian rhythms, melatonin and melatonin agonists.
    Quera Salva MA; Hartley S
    J Cent Nerv Syst Dis; 2012; 4():15-26. PubMed ID: 23650464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine: a novel antidepressant.
    Sansone RA; Sansone LA
    Innov Clin Neurosci; 2011 Nov; 8(11):10-4. PubMed ID: 22191083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α
    M'Dahoma S; Poitevin M; Dabala E; Payan H; Gabriel C; Mocaër E; Bourgoin S; Hamon M
    Front Pharmacol; 2018; 9():587. PubMed ID: 29930510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
    De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
    Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.
    Gahr M
    Curr Neuropharmacol; 2014 Sep; 12(5):287-398. PubMed ID: 25426008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
    Laudon M; Frydman-Marom A
    Int J Mol Sci; 2014 Sep; 15(9):15924-50. PubMed ID: 25207602
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.